CN-121987612-A - Application of sodium glucose cotransporter 2 inhibitor in preparation of anti-aging drugs

Abstract

The invention provides application of a sodium glucose cotransporter 2 inhibitor in preparing a medicament for preventing or treating aging. In an aging animal model, the sodium glucose cotransporter 2 inhibitor, engagliflozin, can improve heart aging, enhance heart functions caused by aging, improve left ventricular ejection fraction, improve memory functions caused by aging, and improve expression levels of aging factors p16, p21 and p 53. The sodium glucose cotransporter 2 inhibitor Engliflozin has the prospect of being developed as an anti-aging drug.

Inventors

• CHEN PEIYUN
• LIU DONGFANG

Assignees

• 重庆医科大学附属第二医院

Dates

Publication Date

20260508

Application Date

20260322

Claims (7)

1. 1. The application of the sodium glucose cotransporter 2 inhibitor in preparing the anti-aging drugs is provided, wherein the sodium glucose cotransporter 2 inhibitor is englitjing, and the structural formula of the englitjing is as follows: 。
2. 2. The method of claim 1, wherein the aging is heart aging.
3. 3. The use according to claim 2, wherein the use is for improving cardiac function.
4. 4. The method of claim 3, wherein the method further comprises increasing left ventricular ejection fraction.
5. 5. The use according to claim 1, wherein the aging is brain aging.
6. 6. The use according to claim 5, wherein the use is for improving memory function.
7. 7. The method of claim 1, wherein the method comprises increasing the expression levels of p16, p21, and p 53.

Description

Application of sodium glucose cotransporter 2 inhibitor in preparation of anti-aging drugs Technical Field The invention belongs to the technical field of biological medicines, relates to research and development of anti-aging medicines, and in particular relates to application of a sodium glucose cotransporter 2 inhibitor in preparation of an anti-aging medicine. Background Cell senescence is an irreversible state of cell cycle arrest associated with aging. Cell aging can lead to cell cycle arrest, shortening of telomeres, decreased mitochondrial function, etc. With the increasing degree of aging in China, the physiological level caused by aging declines, and great threat is brought to the life and health of the aged. Aging can result in changes in cardiac structure and function, such as changes in vascular morphology including intimal thickening, vascular stiffening, atherosclerotic plaque formation, etc. Heart function decreases, left ventricle mass, thickness and diameter increase, ejection fraction decreases, and systolic pressure increases. And endothelial dysfunction, the inhibition of angiogenesis due to endothelial cell aging, increased oxidative stress and inflammation. The research status of the mechanism comprises cell aging, cell cycle arrest, telomere shortening, mitochondrial function reduction and the like. Oxidative stress levels increase during aging, resulting in vascular and cardiac tissue damage, and inflammatory responses in the aging heart and blood vessels are exacerbated, promoting atherosclerosis and plaque instability. Engliflozin is a sodium-glucose co-transporter 2 (SGLT 2) inhibitor that promotes urinary glucose excretion by inhibiting the activity of sodium-glucose co-transporter 2 (SGLT 2) receptor protein on the proximal tubule, and increases glucose excretion in urine, thereby reducing fasting and postprandial blood glucose. Disclosure of Invention The invention aims to provide application of a sodium glucose cotransporter 2 inhibitor in preparing medicines for preventing or treating aging. The invention adopts the following technical scheme: use of sodium glucose cotransporter 2 inhibitor in preparing medicine for preventing or treating aging is provided. According to one embodiment of the invention, the sodium glucose cotransporter 2 inhibitor is engagliflozin. The structural formula of the englitjing is as follows: Engliflozin According to one embodiment of the invention, the aging is heart aging. According to one embodiment of the invention, the use is to improve cardiac function. According to one embodiment of the invention, the use is to increase left ventricular ejection fraction. According to one embodiment of the invention, the aging is brain aging. According to one embodiment of the invention, the application is to improve memory function. According to one embodiment of the invention, the use is to increase the expression level of p16, p21, p 53. Advantageous effects The invention provides application of a sodium glucose cotransporter 2 inhibitor in preparing a medicament for preventing or treating aging. In an aging animal model, the sodium glucose cotransporter 2 inhibitor, engagliflozin, can improve heart aging, enhance heart functions caused by aging, improve left ventricular ejection fraction, improve memory functions caused by aging, and improve expression levels of aging factors p16, p21 and p 53. The sodium glucose cotransporter 2 inhibitor Engliflozin has the prospect of being developed as an anti-aging drug. Drawings Fig. 1 is a graph showing the results of expression of cardiac fibrosis index α -SMA, collagen I in mice of each group, P <0.05, P <0.01. Fig. 2 is a graph showing the results of comparison of mice heart tissue masson and sirius red staining groups, P <0.001, P <0.01. Fig. 3 is a graph of the effect of englitine on left heart ejection fraction of mice in each group, P <0.001, P <0.01. Fig. 4 is a graph of the effect of englitjing on spatial learning memory in senescent mice, P <0.05, P <0.01. Fig. 5 is a graph of the effect of englitjing on H 2O2 -induced AC16 cell senescence-associated protein, P <0.001, P <0.01, P <0.05. Detailed Description In the following examples, the present invention is described only exemplarily, but various modifications of the present invention can be made by those skilled in the art after reading the present patent application without departing from the spirit and scope of the present invention. Example 1 animal experiment (1) Animal model construction C57BL/6J Male mice, 16 months and 2 months old, purchased from Dashuo animal Co., ltd, were bred in an affiliated second hospital animal laboratory at Chongqing medical university. Animal facilities maintain normal 12 hours of light and dark circulation throughout the day and night, and mice are free to obtain food and water. 16 month-Old mice were randomly divided into two groups of 15 EMPA (30 mg/kg/d) and natural aging (Old) groups. 10 Young mice (Young group) w